Diabetes Devices (BGM, Insulin Delivery) Market Worth $41.6 Billion by 2027: Key Insights & Opportunities - ResearchAndMarkets.com

DUBLIN--()--The "Diabetes Devices Market Size, Share & Trends Analysis Report by Product (BGM Devices, Insulin Delivery Devices) by Distribution Channel, by End Use (Hospitals, Homecare), by Region, and Segment Forecasts, 2020-2027" report has been added to ResearchAndMarkets.com's offering.

The global diabetes devices market size is expected to reach USD 41.6 billion by 2027, registering a CAGR of 7.8% over the forecast period.

The market is driven by factors such as increasing incidence of diabetes, technological advancements, and innovative product launches. Increasing adoption of advanced diabetes management solutions in developing region, government policies, and rising medical tourism are some of the major factors contributing to the market growth. Furthermore, rising government initiatives to spread awareness about diabetes and increasing R&D expenditure of major players are the factors expected to boost market growth.

According to a study published on National Center for Biotechnology Information (NCBI), global health expenditure on diabetes is expected to reach USD 490 billion in 2030 from 376 billion in 2010. Obesity, sedentary lifestyle, and fast food culture are some of the factors expected to have significant impact on the market growth. According to Harvard T.H. Chan School of Public Health, U.S. has the highest rates of obesity and it is expected to increase up to 50% by 2030.

In addition, increasing number of new market players, who focus on patient convenience with the help of artificial intelligence technology, are also transforming the market. They are leveraging technological advancements to improve diabetes care solutions like CGM devices, non-invasive insulin delivery systems, and digital diabetes management platforms. For instance, in December 2017, Companion Medical Launched Inpen, its first smart insulin pen system in the U.S. It is the only FDA approved device that can combine insulin injector pen with a smart app.

Further key findings from the report suggest:

  • North America accounted for the largest share in 2019, in terms of revenue, owing to favorable reimbursement policies, presence of key players, and frequent product launches
  • By product, the insulin delivery devices segment accounted for the largest market share and is also expected to grow at the fastest rate
  • In the Blood Glucose Monitoring (BGM) segment, self-monitoring devices dominated the market owing to their low cost and high usage
  • In Self-monitoring of Blood Glucose (SMBG) devices, testing strips segment dominated the market while blood glucose meters are expected to grow at a significant pace owing to high adoption and technological advancements
  • In the Continuous Glucose Monitoring (CGM) devices segment, transmitters accounted for the largest share owing to high cost of devices and high usage
  • In insulin delivery devices, pens segment dominated the market since it is easy to carry, easy to use, and has low cost as compared to other delivery devices
  • By distribution channel, hospital pharmacy segment dominated the market owing to rise in sales of diabetes devices in these pharmacies
  • By end use, hospital segment accounted for the largest market share owing to improving healthcare infrastructure due to rising investment
  • The leading players present in the diabetes devices market are Medtronic plc, Abbott Laboratories, F.Hoffmann-La-Ltd, Bayer AG, Lifescan, Inc., B Braun Melsungen AG, Lifescan, Inc., Dexcom Inc., Insulet Corporation, Ypsomed Holdings, Companion Medical, Sanofi, Valeritas Holding Inc., Novo Nordisk, Arkray, Inc., among others

Key Topics Covered

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

2.1. Market Outlook

2.2. Segment Outlook

2.2.1. Product Outlook

2.2.2. Regional Outlook

2.3. Competitive Insights

Chapter 3. Diabetes Devices Market Variables, Trends & Scope

3.1. Market Lineage Outlook

3.1.1. Parent Market Outlook

3.1.2. Related/Ancillary Market Outlook

3.2. Penetration & Growth Prospect Mapping

3.3. Industry Value Chain Analysis

3.3.1. Reimbursement Framework

3.4. Market Dynamics

3.4.1. Market Driver Analysis Rising Prevalence of Diabetes Increasing Geriatric Population Technological Advancement in Diabetes Devices Rising Awareness About Diabetes Preventive Care

3.4.2. Market Restraint Analysis Low Per Capita Expenditure on Diabetes Lack of Reimbursement and Stringent Regulations in Few Countries

3.4.3. Industry Challenges

3.5. Diabetes Devices Market Analysis Tools

3.5.1. Industry Analysis - Porter's

3.5.2. PESTEL Analysis

3.5.3. Major Deals & Strategic Alliances Analysis

3.5.4. Market Entry Strategies

Chapter 4. Diabetes Devices Market by Product Estimates & Trend Analysis

4.1. Definitions and Scope

4.1.1. BGM Devices

4.1.2. Insulin Delivery Devices

4.2. Product Market Share, 2019 & 2027

4.3. Segment Dashboard

4.4. Global Diabetes Devices Market by Product Outlook

4.4.1. BGM Devices

Chapter 5. Diabetes Devices Market: Distribution Channel Estimates & Trend Analysis

5.1. Definitions and Scope

5.1.1. Hospital Pharmacies

5.1.2. Retail Pharmacies

5.1.3. Diabetes Clinics/ Centers

5.1.4. Online Pharmacies

5.1.5. Others

5.2. Product Market Share, 2019 & 2027

5.3. Segment Dashboard

5.4. Global Diabetes Devices Market by Distribution Channel Outlook

5.4.1. Hospital Pharmacies

5.4.2. Retail Pharmacies

5.4.3. Diabetes Clinics/Centers

5.4.4. Online Pharmacies

5.4.5. Others

Chapter 6. Diabetes Devices Market: End Use Estimates & Trend Analysis

6.1. Definitions and Scope

6.1.1. Hospitals

6.1.2. Homecare

6.1.3. Diagnostic Centers

6.2. Product Market Share, 2019 & 2027

6.3. Segment Dashboard

6.4. Global Diabetes Devices Market by End Use Channel Outlook

6.4.1. Hospitals

6.4.2. Homecare

6.4.3. Diagnostic Centers

Chapter 7. Diabetes Devices Market: Country Estimates & Trend Analysis

7.1. Country Market Share Analysis, 2019 & 2027

7.2. County Market Dashboard

7.3. Regional Market Snapshot

7.4. Regional Market Share and Leading Players, 2019

7.5. SWOT Analysis, by Factor (Political & Legal, Economic and Technological)

7.6. Market Size, & Forecasts, Volume and Trend Analysis, 2019 to 2027

7.7. North America

7.8. Europe

7.9. Asia-Pacific

7.10. Latin America

7.11. Middle East & Africa

Chapter 8. Competitive Landscape

8.1. Recent Developments & Impact Analysis, by Key Market Participants

8.2. Company/Competition Categorization

8.2.1. Innovators

8.3. Vendor Landscape

8.3.1. List of Key Distributors and Channel Partners

8.3.2. Key Customers

8.3.3. Key Company Market Share Analysis, 2019

8.3.4. Medtronic PLC

8.3.5. Abbott Laboratories

8.3.6. Arkray, Inc

8.3.7. B Braun Melsungen AG

8.3.8. Bayer Corporation

8.3.9. Dexcom Inc.

8.3.10. F Hoffmann-La Roche AG

8.3.11. LifeScan, Inc.

8.3.12. Sanofi

8.3.13. Insulet Corporation

8.3.14. Novo Nordisk

8.3.15. Ypsomed Holding AG

8.3.16. Valeritas Holdings Inc.

For more information about this report visit https://www.researchandmarkets.com/r/ykb3z0


Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900


Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900